We are live on ! Find out more

1,606 hedge funds and large institutions have $133B invested in Pfizer in 2013 Q3 according to their latest regulatory filings, with 72 funds opening new positions, 616 increasing their positions, 724 reducing their positions, and 77 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more call options, than puts

Call options by funds: $1.22B | Put options by funds: $1.16B

0.06% more ownership

Funds ownership: 73.6%73.66% (+0.06%)

4% less capital invested

Capital invested by funds: $139B → $133B (-$5.46B)

6% less first-time investments, than exits

New positions opened: 72 | Existing positions closed: 77

1% less funds holding

Funds holding: 1,6271,606 (-21)

12% less funds holding in top 10

Funds holding in top 10: 290254 (-36)

15% less repeat investments, than reductions

Existing positions increased: 616 | Existing positions reduced: 724

Holders
1,606
Holders Change
-21
Holders Change %
-1.29%
% of All Funds
52.06%
Holding in Top 10
254
Holding in Top 10 Change
-36
Holding in Top 10 Change %
-12.41%
% of All Funds
8.23%
New
72
Increased
616
Reduced
724
Closed
77
Calls
$1.22B
Puts
$1.16B
Net Calls
+$60.2M
Net Calls Change
+$43.7M
Name Holding Trade Value Shares
Change
Change in
Stake
MIP
201
Mondrian Investment Partners
United Kingdom
$76.2M -$22.2M -817,166 -23%
SCM
202
Shapiro Capital Management
Georgia
$74.5M +$5.97M +219,233 +9%
Two Sigma Advisers
203
Two Sigma Advisers
New York
$74.3M +$73.8M +2,713,840 +21,680%
MPI
204
Mairs & Power Inc
Minnesota
$74.2M -$1.01M -37,052 -1%
MP
205
MSD Partners
New York
$74.2M -$71.7M -2,635,000 -49%
TAM
206
Tocqueville Asset Management
New York
$74.2M -$3.49M -128,278 -5%
MAMU
207
Marathon Asset Management (UK)
United Kingdom
$73.6M +$7.65M +281,073 +12%
KBG
208
Kahn Brothers Group
New York
$72M -$964K -35,436 -1%
SIA
209
Sit Investment Associates
Minnesota
$71.6M -$24.1K -885 -0%
DekaBank Deutsche Girozentrale
210
DekaBank Deutsche Girozentrale
Germany
$71.3M -$7.04M -258,744 -9%
First Trust Advisors
211
First Trust Advisors
Illinois
$71.3M +$15M +552,208 +27%
GC
212
Guggenheim Capital
Illinois
$67.9M -$2.06M -75,871 -3%
Brown Advisory
213
Brown Advisory
Maryland
$67.8M -$1.73M -63,519 -2%
PIA
214
Piedmont Investment Advisors
North Carolina
$67.5M +$18.8M +692,627 +39%
HFS
215
HL Financial Services
Kentucky
$66.4M +$1.34M +49,222 +2%
SCP
216
Seizert Capital Partners
Michigan
$66.3M -$5.38M -197,624 -8%
CB
217
Commerce Bank
Missouri
$66.2M +$662K +24,335 +1%
BFM
218
Boston Financial Management
Massachusetts
$66.1M +$15.6K +575 +0%
RIG
219
Roosevelt Investment Group
New York
$65.7M -$3.35M -123,176 -5%
RCAMU
220
Rothschild & Co Asset Management US
Connecticut
$65.2M -$199K -7,308 -0.3%
TSU
221
TD Securities (USA)
New York
$65.1M -$249K -9,153 -0.4%
HCM
222
Huber Capital Management
California
$64.8M +$1.02M +37,311 +2%
FCAM
223
F&C Asset Management
United Kingdom
$64.5M -$1.32M -48,415 -2%
Fidelity International
224
Fidelity International
Bermuda
$64M -$146M -5,376,899 -70%
GF
225
Gabelli Funds
New York
$63.9M -$40.1K -1,475 -0.1%

PFE Hedge Fund Activity: Q3 2013 in Review

1,606 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q3 2013, worth a combined $133B — down 3.9% from $139B a quarter earlier.

Sellers outnumbered buyers: 77 funds closed out of PFE and 72 opened new positions — a net loss of 5 holders — while 724 trimmed existing stakes and 616 added.

The largest buyer was Capital World Investors, adding an estimated $294M. The largest seller was Susquehanna International Group, cutting an estimated $887M.

  • 1,606 institutional investors held Pfizer (PFE) as of Q3 2013, down from 1,627 in Q2 2013.
  • Funds reported $133B of Pfizer stock for Q3 2013, down 3.9% quarter-over-quarter.
  • 72 funds opened new Pfizer positions in Q3 2013 and 77 closed out, a net change of -5 holders.
  • The largest Pfizer buyer in Q3 2013 was Capital World Investors, an estimated $294M added.
  • The largest Pfizer seller in Q3 2013 was Susquehanna International Group, an estimated $887M sold.

Based on aggregated 13F filings for Q3 2013.